Dravet综合征
癫痫
医学
药物开发
变构调节
变构调节剂
药理学
发作类型
神经科学
精神科
受体
心理学
药品
内科学
作者
Meir Bialer,Svein I. Johannessen,Matthias J. Koepp,Emilio Perucca,Piero Perucca,Torbjörn Tomson,H. Steve White
出处
期刊:Epilepsia
[Wiley]
日期:2024-08-22
卷期号:65 (10): 2858-2882
被引量:11
摘要
The 17th Eilat Conference on New Antiepileptic Drugs and Devices took place in Madrid, Spain on May 5-8, 2024. As usual, the core part of the conference consisted of presentations on investigational drugs at various stages of development for epilepsy-related indications. Summaries of information on compounds in preclinical or early clinical development are included in an accompanying publication (Part I). In this article, we provide summaries for five compounds in more advanced clinical development, i.e. compounds for which some information on antiseizure activity in individuals with epilepsy is available. These investigational treatments include azetukalner (XEN1101), a potent, K
科研通智能强力驱动
Strongly Powered by AbleSci AI